Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

The introduction of second-generation androgen receptor antagonists (SG-ARAs) has
greatly impacted the treatment of metastatic prostate cancer, providing tolerable and …

Background The phase 3 SPARTAN study evaluated apalutamide versus placebo in
patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate …

Ferroptosis is a type of programmed cell death induced by the accumulation of lipid
peroxidation and lipid reactive oxygen species in cells. It has been recently demonstrated …

Simple Summary Early-stage and castration-sensitive prostate cancer (PCa) growth is solely
mediated by androgen signaling pathways. AR signaling inhibitors (ARSIs) have …

The treatment landscape of advanced prostate cancer has widely expanded over the past
years with androgen receptor signaling inhibitors (ARSIs) and taxane chemotherapy moving …

Background Emerging data suggest that patients with enzalutamide-treated prostate cancer
with increased programmed death-ligand 1 (PD-L1) expression may benefit from anti-PD-L1 …

Background Despite the advent of improved therapeutic options for advanced prostate
cancer, the durability of clinical benefits is limited due to inevitable development of …

Castration-resistant prostate cancer (CRPC) presents significant challenges in clinical
management due to its resistance to conventional androgen receptor (AR)-targeting …

Prostate cancer therapy for locally advanced and metastatic diseases includes androgen
deprivation therapy (ADT). Second-generation antiandrogens have a role in castration …